Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Receivables - Net: 2010-2025

Historic Receivables - Net for Heron Therapeutics (HRTX) over the last 9 years, with Sep 2025 value amounting to $81.0 million.

  • Heron Therapeutics' Receivables - Net rose 20.90% to $81.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.0 million, marking a year-over-year increase of 20.90%. This contributed to the annual value of $78.9 million for FY2024, which is 31.17% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Receivables - Net is $81.0 million, which was up 1.40% from $79.9 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Receivables - Net ranged from a high of $81.0 million in Q3 2025 and a low of $35.5 million during Q4 2021.
  • In the last 3 years, Heron Therapeutics' Receivables - Net had a median value of $73.7 million in 2024 and averaged $70.6 million.
  • As far as peak fluctuations go, Heron Therapeutics' Receivables - Net decreased by 15.18% in 2021, and later surged by 90.29% in 2023.
  • Heron Therapeutics' Receivables - Net (Quarterly) stood at $35.5 million in 2021, then soared by 46.62% to $52.0 million in 2022, then rose by 15.54% to $60.1 million in 2023, then spiked by 31.17% to $78.9 million in 2024, then climbed by 20.90% to $81.0 million in 2025.
  • Its last three reported values are $81.0 million in Q3 2025, $79.9 million for Q2 2025, and $78.7 million during Q1 2025.